TY - JOUR
T1 - Endoscopic Treatment of Superficial Gastric Cancer
T2 - Present Status and Future
AU - Hisada, Hiroyuki
AU - Sakaguchi, Yoshiki
AU - Oshio, Kaori
AU - Mizutani, Satoru
AU - Nakagawa, Hideki
AU - Sato, Junichi
AU - Kubota, Dai
AU - Obata, Miho
AU - Cho, Rina
AU - Nagao, Sayaka
AU - Miura, Yuko
AU - Mizutani, Hiroya
AU - Ohki, Daisuke
AU - Yakabi, Seiichi
AU - Takahashi, Yu
AU - Kakushima, Naomi
AU - Tsuji, Yosuke
AU - Yamamichi, Nobutake
AU - Fujishiro, Mitsuhiro
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/7
Y1 - 2022/7
N2 - Although the mortality rates of gastric cancer (GC) are gradually declining, gastric cancer is still the fourth leading cause of cancer-related death worldwide. This may be due to the high rate of patients who are diagnosed with GC at advanced stages. However, in countries such as Japan with endoscopic screening systems, more than half of GCs are discovered at an early stage, enabling endoscopic resection (ER). Especially after the introduction of endoscopic submucosal dissection (ESD) in Japan around 2000, a high en bloc resection rate allowing pathological assessment of margin and depth has become possible. While ER is a diagnostic method of treatment and may not always be curative, it is widely accepted as standard treatment because it is less invasive than surgery and can provide an accurate diagnosis for deciding whether additional surgery is necessary. The curability of ER is currently assessed by the completeness of primary tumor removal and the possibility of lymph node metastasis. This review introduces methods, indications, and curability criteria for ER of EGC. Despite recent advances, several problems remain unsolved. This review will also outline the latest evidence concerning future issues.
AB - Although the mortality rates of gastric cancer (GC) are gradually declining, gastric cancer is still the fourth leading cause of cancer-related death worldwide. This may be due to the high rate of patients who are diagnosed with GC at advanced stages. However, in countries such as Japan with endoscopic screening systems, more than half of GCs are discovered at an early stage, enabling endoscopic resection (ER). Especially after the introduction of endoscopic submucosal dissection (ESD) in Japan around 2000, a high en bloc resection rate allowing pathological assessment of margin and depth has become possible. While ER is a diagnostic method of treatment and may not always be curative, it is widely accepted as standard treatment because it is less invasive than surgery and can provide an accurate diagnosis for deciding whether additional surgery is necessary. The curability of ER is currently assessed by the completeness of primary tumor removal and the possibility of lymph node metastasis. This review introduces methods, indications, and curability criteria for ER of EGC. Despite recent advances, several problems remain unsolved. This review will also outline the latest evidence concerning future issues.
KW - curability assessment
KW - endoscopic diagnosis
KW - endoscopic resection
KW - endoscopic screening
KW - endoscopic submucosal dissection
KW - gastric cancer
UR - http://www.scopus.com/inward/record.url?scp=85133689200&partnerID=8YFLogxK
U2 - 10.3390/curroncol29070371
DO - 10.3390/curroncol29070371
M3 - Review article
C2 - 35877231
AN - SCOPUS:85133689200
SN - 1718-7729
VL - 29
SP - 4678
EP - 4688
JO - Current Oncology
JF - Current Oncology
IS - 7
ER -